Trial Profile
Pilot Clinical Trial of Neoadjuvant SGLT2 Inhibition in High-Risk Localized Prostate Cancer
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 25 Jan 2024
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 19 Jan 2024 Planned End Date changed from 28 Feb 2027 to 30 Jun 2027.
- 19 Jan 2024 Planned primary completion date changed from 28 Feb 2027 to 30 Jun 2027.
- 19 Jan 2024 Planned initiation date changed from 31 Dec 2023 to 30 Apr 2024.